---
title: "Citius Oncology, Inc. (CTOR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CTOR.US.md"
symbol: "CTOR.US"
name: "Citius Oncology, Inc."
industry: "生物技術"
---

# Citius Oncology, Inc. (CTOR.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |

## Company Profile

Citius Oncology, Inc. 專注于創新靶向腫瘤治療的開發和商業化。它還參與開發 LYMPHIR，這是一種針對复發或難治性皮膚 T 細胞淋巴瘤成年患者的孤兒適應症，這是一種罕見的非霍奇金淋巴瘤。該公司總部位于新澤西州克蘭福德

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-28T04:30:15.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 278 / 399 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -2.41% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.69 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 98.87M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.94M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -47.41% | E |
| Profit Margin | -599.28% | E |
| Gross Margin | 79.99% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | -2.41% | C |
| Total Assets YoY | 21.54% | A |
| Net Assets YoY | 41.47% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -16.69% | D |
| OCF YoY | 0.00% | C |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.04 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 46.88% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Citius Oncology, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-47.41%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-599.28%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "79.99%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.41%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.54%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "41.47%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-16.69%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "46.88%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.18 | 352/606 | - | - | - |
| PB | 1.69 | 144/606 | 4.57 | 2.91 | 1.69 |
| PS (TTM) | 25.07 | 208/606 | 26.41 | 25.96 | 24.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-17T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 1 | 100% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.12 |
| Highest Target | 6.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CTOR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CTOR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CTOR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.